Change in Off-Label Use of Bone Morphogenetic Protein in Spine Surgery and Associations with Adverse Outcome

Study Design Retrospective cohort study. Objective The U.S. Food and Drug Administration issued a warning in 2008 against off-label bone morphogenetic protein (BMP-2) use. We aimed to determine (off-label) BMP-2 use in two periods and associations with complications. Methods We included 340,393 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Poeran, Jashvant, Opperer, Mathias, Rasul, Rehana, Mazumdar, Madhu, Girardi, Federico P., Hughes, Alexander P., Memtsoudis, Stavros G., Vougioukas, Vassilios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5077709/
https://www.ncbi.nlm.nih.gov/pubmed/27781184
http://dx.doi.org/10.1055/s-0036-1571284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5077709/
https://www.ncbi.nlm.nih.gov/pubmed/27781184
http://dx.doi.org/10.1055/s-0036-1571284

Ejemplares similares